Parameter
| Biomarker | SH3GL1 | Full name | SH3 domain containing GRB2 like 1 | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, therapeutic targets | ||
| Disease | Non-Hodgkin Lymphoma (NHL) | Disease Subtypes | / | ||
| Organ | Lymphoid tissue | Test Sample / Technology Platform | Tissues, cell lines (immunohistochemistry, CRISPR editing) | ||
| Pathobiological Mechanisms | High expression inhibits ferroptosis and adriamycin resistance, associated with poor prognosis | ||||
| Clinical Availability Status | Research validation phase: 126 patients and cell experiment validation, requiring dynamic monitoring and drug development | ||||
| Notes and Dynamics | Developing detection antibodies and exploring targeted ferroptosis combined with chemotherapy strategies. | ||||